SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-25-001787
Filing Date
2025-01-10
Accepted
2025-01-10 17:18:53
Documents
64
Period of Report
2024-10-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 1073090
2 ex14.htm EX-14 47990
3 ex23-1.htm EX-23.1 3738
4 ex31-1.htm EX-31.1 17286
5 ex31-2.htm EX-31.2 17331
6 ex32-1.htm EX-32.1 6566
7 ex32-2.htm EX-32.2 6575
  Complete submission text file 0001493152-25-001787.txt   5400193

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE anix-20241031.xsd EX-101.SCH 31630
9 XBRL CALCULATION FILE anix-20241031_cal.xml EX-101.CAL 50266
10 XBRL DEFINITION FILE anix-20241031_def.xml EX-101.DEF 166508
11 XBRL LABEL FILE anix-20241031_lab.xml EX-101.LAB 360841
12 XBRL PRESENTATION FILE anix-20241031_pre.xml EX-101.PRE 286068
67 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 710136
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

IRS No.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-K | Act: 34 | File No.: 001-37492 | Film No.: 25523959
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)